Stephen Anesi is an Ophthalmology physician affiliated with Ocular Immunology and Uveitis Foundation. OpenAlex indexes 71 publications with 864 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1440 Main Street
Suite 201
Waltham, MA 02451
Telephone
781-891-6377Registry record last updated 18 Oct 2019.
Industry payments
44 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mallinckrodt Hospital Products Inc.Program year202588 payments$108,315openpaymentsdata.cms.gov ↗
- ANI Pharmaceuticals, Inc.Program year202535 payments$23,510openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202529 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
36.2%alpha-Adrenergic Agonist8.1%Brimonidine Tartrate53%Alphagan P21%Brimonidine Tartrate-Timolol15%Combigan12%Part D≥57 patientsCarbonic Anhydrase Inhibitor7.4%Dorzolamide-Timolol50%Dorzolamide Hcl22%Simbrinza13%Brinzolamide11%Cosopt Pf4%Part D<11 patients+ 9 more classes in this area
Cancer & immunology
27.8%Folate Analog Metabolic Inhibitor11.6%Methotrexate100%Part D≥127 patientsCalcineurin inhibitor7.3%Cyclosporine Modified51%Restasis30%Cequa14%Cyclosporine5%Part D<11 patients+ 6 more classes in this area
Anti-infectives
12.5%Tetracycline-class Drug4.5%Doxycycline Hyclate94%Doxycycline Monohydrate6%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.5%Valacyclovir100%Part D≥68 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Updates on Systemic Immunomodulation in Peripheral Ulcerative Keratitis
Journal of Clinical & Translational Ophthalmology
2024 - Outcomes of Intravenous Tocilizumab Treatment for Refractory Pars Planitis
Ocular Immunology and Inflammation
2024 - Candy Cane Hypopyon Secondary to Intraocular Mantle Cell Lymphoma: A Case Report
Case Reports in Ophthalmology
2024 - Implantation of XEN gel stent in a patient with ocular cicatricial pemphigoid
American Journal of Ophthalmology Case Reports
2023 - Vision Outcomes of Long-Term Immunomodulatory and Steroid Therapy in Sympathetic Ophthalmia
American Journal of Ophthalmology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”